Regeneron’s 400,000 square foot, state-of-the-art Industrial Operations and Product Supply (IOPS) facility in Raheen Business Park, Limerick is the largest-scale bulk biologics Active Pharmaceutical Ingredient (API) production facility in Ireland.
The facility became operational in 2015 and following an additional $350 million investment will add another 200 jobs, bringing the total expected job creation in the Limerick area to 500 jobs and total investment to $650 million by the end of 2017.
IOPS is responsible for the production, packaging, labelling and delivery of Regeneron products. IOPS manufactures a broad range of biopharmaceuticals for patients worldwide, including therapeutic proteins approved for marketing by regional or national regulatory agencies and those involved in clinical studies.
About choosing to locate in Limerick, Regeneron Executive Vice-President, Dan Van Plew said "We have been impressed by the positive, can-do attitude of the local community and the support we have received at every stage of this process. Thank you for the warmth of your welcome and for making us feel at home here in Limerick."
Regeneron (NASDAQ: REGN) is a leading science-based biopharmaceutical company that discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions. Regeneron commercializes medicines for high LDL cholesterol, eye diseases, and a rare inflammatory condition and has product candidates in development in other areas of high unmet medical need, including oncology, rheumatoid arthritis, asthma, atopic dermatitis, pain, and infectious diseases. For additional information about the company, please visit www.regeneron.com or follow @Regeneron on Twitter.